These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 7044448)
1. Protein A adsorption of acute myelogenous leukemia serum induces in vitro blast lysis. Miller WJ; Branda RF; Hurd DD; Wachsman W; Nelson NL; Jacob HS Blood; 1982 Jun; 59(6):1344-7. PubMed ID: 7044448 [TBL] [Abstract][Full Text] [Related]
2. In vitro tumoricidal activity of immunoadsorbed leukemic serum. Miller WJ; Branda RF J Biol Response Mod; 1984; 3(3):231-4. PubMed ID: 6379106 [TBL] [Abstract][Full Text] [Related]
3. Effects of staphylococcal protein A-treated human leukemic serum on autologous leukemic blast growth and mitogenesis of lymphocytes. Spitzer TR; Lazarus HM J Clin Immunol; 1984 Nov; 4(6):455-60. PubMed ID: 6392315 [TBL] [Abstract][Full Text] [Related]
4. Effects of ex-vivo plasma adsorption over protein A sepharose in acute leukemia. Solal-Celigny P; Simeon J; Herrera A; Vinci G; Bertrand O; Mahieu P; Kinet JP; Raspaud S; Sinegre M; Boivin P Leuk Res; 1986; 10(6):643-9. PubMed ID: 3520164 [TBL] [Abstract][Full Text] [Related]
5. Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation. Bruserud O; Ulvestad E J Hematother Stem Cell Res; 1999 Aug; 8(4):431-41. PubMed ID: 10634181 [TBL] [Abstract][Full Text] [Related]
6. Further characterization of the in vitro tumoricidal activity of staphylococcal protein A. Branda RF; Miller WJ; Soltis RD Cancer Res; 1986 May; 46(5):2610-3. PubMed ID: 3698001 [TBL] [Abstract][Full Text] [Related]
7. Studies on the ability of monoclonal antibodies to selectively mediate complement-dependent cytotoxicity of human myelogenous leukemia blast cells. Ball ED; Kadushin JM; Schacter B; Fanger MW J Immunol; 1982 Mar; 128(3):1476-81. PubMed ID: 6948897 [TBL] [Abstract][Full Text] [Related]
8. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance. Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919 [TBL] [Abstract][Full Text] [Related]
9. Possibly specific immune complexes in sera of patients with untreated acute myelogenous leukemia. Fäldt R; Ankerst J Int J Cancer; 1980 Sep; 26(3):309-14. PubMed ID: 6945292 [TBL] [Abstract][Full Text] [Related]
10. Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Weidmann E; Brieger J; Jahn B; Hoelzer D; Bergmann L; Mitrou PS Ann Hematol; 1995 Mar; 70(3):153-8. PubMed ID: 7718644 [TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932 [TBL] [Abstract][Full Text] [Related]
13. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells. Notter M; Ludwig WD; Bremer S; Thiel E Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036 [TBL] [Abstract][Full Text] [Related]
14. Specificity of heteroantisera to human acute leukemia-associated antigens. Baker MA; Ramachandar K; Taub RN J Clin Invest; 1974 Dec; 54(6):1273-8. PubMed ID: 4140196 [TBL] [Abstract][Full Text] [Related]
15. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Archimbaud E; Bailly M; Doré JF Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757 [TBL] [Abstract][Full Text] [Related]
16. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Notter M; Willinger T; Erben U; Thiel E Blood; 2001 May; 97(10):3138-45. PubMed ID: 11342441 [TBL] [Abstract][Full Text] [Related]